# Pizarra — PT-pseudo_4a2fa7bc3595 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a2fa7bc3595
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.257 ng/mL²
  - PSA velocity: -0.62 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 26.9 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84531116 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 106/78 mmHg, HR 71 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2006).

Chief complaint: Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels.

History: At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities.

Physical examination: DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement.

Patient info: retired electrical engineer; Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 3 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.21   (95% CI 0.06-0.83)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 5.0 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=6.9, age=67.0, psad=0.257, dre_ord=1.0, vol=26.9, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (-0.62 ng/mL/yr) or the full context of the mpMRI report (beyond the PI-RADS 5 score) or the specific findings from the laboratory panel.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.41 +/- 0.21), indicating high uncertainty. A failure mode is the high csPCa predicted probability (0.84531116) conflicting with the 'NO BIOPSY' suggestion, suggesting the prior underestimated the risk. Another failure mode is the DRE finding ('Nodus') being ambiguous, as the prior did not see the full context of the physical exam findings or the specific MRI details.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details specific features of the PI-RADS 5 lesion (e.g., atypicalis, microcalcifications), it would refine the risk assessment.
  <document> PSA history (trend) -> If the trend shows a significant rise despite the negative velocity, it would increase suspicion for progression.
  <document> laboratory results (full panel) -> If the lab panel shows any markers that modify the risk profile (e.g., inflammation markers), it could alter the decision threshold.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or follow-up plans that influence the current decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_4a2fa7bc3595", "radiology_report": "Subject: Prostate Multiparametric MRI | Date: 20 February 2025 | Site: Amsterdam UMC, AMC\n\nIndication: Reassessment after a previous positive biopsy result. Current serum PSA reads 6.9 ng/mL.\n\nImaging reveals a glandular volume of 26.9 mL. A distinct hypointense area occupies the right peripheral zone, spanning from the mid-gland down to the apex, with dimensions of roughly 14 by 11 by 10 mm. Diffusion-weighted and ADC sequences highlight pronounced restriction. Dynamic contrast phases show rapid, robust enhancement. Capsular borders remain intact without seminal vesicle infiltration. Pelvic nodal basins appear normal. Skeletal survey shows no malignant deposits.\n\nConclusion: PI-RADS 5 lesion in the right peripheral zone. Prostate volume 26.9 mL yielding a PSA density of 0.257 ng/mL/mL. csPCa predicted probability 0.84531116."}

  **psa_trend**
  {"case_id": "PT-pseudo_4a2fa7bc3595", "psa_trend": [{"date": "Apr 2023", "val": 2.3}, {"date": "Mar 2024", "val": 4.0}, {"date": "Feb 2025", "val": 6.9}]}

  **lab_results**
  {"case_id": "PT-pseudo_4a2fa7bc3595", "laboratory_results": [{"name": "PSA", "val": "6.9 ng/mL", "date": "18 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.29 ng/mL", "date": "18 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "19%", "date": "18 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "15.4 g/dL", "date": "18 Jan 2025", "flag": ""}, {"name": "WBC", "val": "6.4 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "293 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "104 umol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "18 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "13.6 nmol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "79 U/L", "date": "18 Jan 2025", "flag": ""}, {"name": "LDH", "val": "165 U/L", "date": "18 Jan 2025", "flag": ""}]}

  **previous_notes**
  {"case_id": "PT-pseudo_4a2fa7bc3595", "previous_notes": [{"date": "29 Oct 2024", "author": "Dr. M. Jansen (GP)", "text": "Clinic assessment conducted after the first positive prostate biopsy. March 2024 laboratory results recorded a PSA value of 5.6 ng/mL, which triggered a urology consultation for diagnostic workup and magnetic resonance imaging coordination. Conservative observation continued during the waiting period, encompassing standard blood panels and symptom checks. Subsequent tracking captured an increase to 6.9 ng/mL alongside awaiting imaging outcomes, completing the primary care documentation cycle."}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI report: PI-RADS 5 lesion in the right peripheral zone with pronounced diffusion restriction and rapid enhancement.
  - PSA trend: PSA has risen from 4.0 ng/mL (Mar 2024) to 6.9 ng/mL (Feb 2025), indicating a significant rise in PSA over the last 11 months.
  - csPCa predicted probability: 0.84531116

  AGAINST sampling this patient now:
  - PSA velocity: -0.62 ng/mL/yr (suggesting a slight decline in velocity, though the absolute level is high).
  - Previous notes: Patient was on conservative observation following a prior positive biopsy.

WHERE THIS LEANS
  The evidence strongly argues FOR sampling due to the high-risk PI-RADS 5 MRI finding and the concerning upward trend in PSA levels, which contradicts the statistical prior suggesting 'NO BIOPSY'.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the high-risk PI-RADS 5 lesion and the concerning upward trend in PSA levels. Specifically, the PI-RADS 5 finding in the right peripheral zone, combined with a PSA rise from 4.0 ng/mL to 6.9 ng/mL over 11 months, outweighs the statistical prior suggesting deferral. The evidence converges on the need for further tissue sampling to clarify the high-risk findings.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
